A National Strategy, Not a Market Play
Saudi Arabia’s commitment to biotechnology is anchored in Vision 2030 and formalized through the National Biotechnology Strategy, launched in 2024. The strategy sets out clear national ambitions:
- Establish Saudi Arabia as the leading biotech hub in MENA by 2030 and globally by 2040
- Contribute over $34.6 billion to non-oil GDP by 2040 (approximately 3%)
- Create 11,000 high-quality biotech jobs by 2030 and 55,000 by 2040
The strategy focuses on three foundational pillars:
1. Vaccines & Advanced Biologics
Building end-to-end manufacturing capabilities for self-sufficiency and export across the Middle East.
2. Biomanufacturing & Localization
Establishing state-of-the-art bio-manufacturing infrastructure to enable biologics, biosimilars, and advanced therapies — reducing import dependency while strengthening domestic industry.
3. Genomics & Precision Medicine
Expanding national genomic databases, integrating genomic analysis into healthcare, and fostering innovation through improved data access and supportive regulatory policies.
Together, these initiatives signal a structural shift: Saudi Arabia is not aiming to become a buyer of advanced therapies. It is aiming to become a builder of biotech capability.
The Current Climate: An Ecosystem Under Construction
Saudi Arabia is not yet a mature CGT ecosystem. It is an ecosystem under construction.
The Kingdom has:
- Significant sovereign capital
- Political alignment at the highest levels
- A defined national biotech roadmap
- Flagship institutions
- Rapidly developing infrastructure
What it is still building:
- A fully functioning translational engine
- A dense operator base in GMP and regulatory sciences
- A deeply embedded IP-native investment culture
- End-to-end clinical development capacity
The story in Saudi is no longer about ambition. It is about execution.
What Has Shifted in the Last 24 Months?
From Vision to Operational Strategy
The 2024 publication of the National Biotechnology Strategy marked a turning point. Biotechnology moved from aspiration to structured economic pillar — embedded in GDP diversification and healthcare transformation.
From Mega-Infrastructure to Capital Discipline
Recent investment recalibration — including capital reallocation toward Riyadh and Jeddah and away from large-scale speculative builds — reflects a more pragmatic approach.
This is not a retreat from biotech.
It is a shift toward:
- Selective deployment
- Capital efficiency
- De-risked pathways
- Execution-focused growth
For CGT developers, this makes the opportunity more targeted — and potentially more serious.
Clinical Manufacturing Is Becoming Tangible
Institutions such as King Faisal Specialist Hospital & Research Centre are expanding advanced manufacturing capability, including the development of cleanroom infrastructure to support cell and gene therapy production.
In parallel, the Saudi Food and Drug Authority is evolving regulatory pathways aligned with global standards.
At the investment level, the Public Investment Fund and platforms such as Lifera are signalling long-term commitment to building biotech as an industrial sector.
Saudi Arabia is approaching advanced therapies not as procurement — but as nation-building.
Reimbursement as a Strategic Lever
The Ministry of Health has supported structured access pathways for companies including Vertex Pharmaceuticals. Reimbursement mechanisms are being used strategically to enable patient access while laying groundwork for eventual localization.
Access, investment, and industrialization are increasingly linked.
Why Now?
Timing matters.
Saudi’s ecosystem is still being shaped:
- Infrastructure is under development
- Regulatory frameworks are evolving
- Investment structures are being defined
- Clinical trial strategy is taking form
In mature markets, frameworks are fixed. In Saudi Arabia, they are still being written.
That creates a rare window for global developers, CDMOs, investors, and platform companies to help shape:
- Clinical trial design and localization
- Sovereign co-investment models
- Manufacturing partnerships
- Workforce development programs
- Regulatory collaboration
This is ecosystem-building — not incremental expansion.
The Immediate Opportunity: Clinical Trials & Translational Acceleration
For global CGT developers, the near-term opportunity in Saudi Arabia is not purely commercial sales.
It is clinical and translational.
Saudi offers:
- Distinct genetic pools
- High prevalence of inherited disorders
- Significant sickle cell burden
- Large metabolic and cardiovascular patient populations
These cohorts remain underrepresented in global trials.
At a time when advanced therapy developers face recruitment bottlenecks and escalating costs, Saudi Arabia represents a strategically important clinical environment.
Structured effectively, the Kingdom could become:
- A regional clinical trials hub
- A Phase I/II acceleration environment
- A translational partner for academic discovery
- A selective manufacturing foothold for advanced therapies
A Strategic Bridge Between Regions
Global innovation is becoming more fragmented.
China’s advanced therapies ecosystem is rapidly producing assets but faces geopolitical and market access constraints. Western developers are seeking diversified manufacturing and trial geographies. Emerging markets are demanding localized innovation.
Saudi Arabia sits at a strategic intersection.
With capital, regulatory flexibility, and industrial ambition, it has the potential to serve as:
- A clinical bridge
- A co-development partner
- A localization platform
- A regional commercialization hub
The implications extend beyond the Middle East.
Register Your Interest
Why the Global Community Should Engage
Advanced Therapies World Middle East is not a regional gathering. It is a strategic dialogue.
It brings together:
- CGT developers
- Biopharma exploring geographic expansion
- CDMOs evaluating new manufacturing hubs
- Investors assessing sovereign co-investment models
- Platform technology providers
- Regulatory and access strategists
The next era of advanced therapies will be defined by three forces:
- Access
- Industrialization
- Geography
Saudi Arabia is one of the few markets attempting to integrate all three simultaneously.
The question for the global community is no longer whether Saudi will participate in advanced therapies.
It is how — and who will help shape that pathway.
What This Launch Represents
Launching Advanced Therapies World in Riyadh is not simply geographic expansion.
It reflects a structural shift in the global advanced therapies landscape.
Saudi Arabia is transitioning from:
A buyer of innovation
to
A builder of biotech capability.
The transition will not be linear. It will require international collaboration, operational expertise, and disciplined investment.
But it is underway.
And the next chapter of advanced therapies will not be written by North America and Europe alone.
Register Your Interest
)